Kymera Therapeutics, Inc.
KYMR
$43.87
$2.054.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -48.07% | 198.89% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -48.07% | 198.89% | |||
| Cost of Revenue | -2.33% | 11.75% | |||
| Gross Profit | -15.06% | 9.73% | |||
| SG&A Expenses | 8.44% | -0.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.51% | 9.50% | |||
| Operating Income | -13.61% | 7.84% | |||
| Income Before Tax | -16.82% | 7.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.82% | 7.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.82% | 7.31% | |||
| EBIT | -13.61% | 7.84% | |||
| EBITDA | -14.91% | 9.72% | |||
| EPS Basic | -16.38% | 7.48% | |||
| Normalized Basic EPS | -16.39% | 7.49% | |||
| EPS Diluted | -16.38% | 7.48% | |||
| Normalized Diluted EPS | -16.39% | 7.49% | |||
| Average Basic Shares Outstanding | 0.38% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.38% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||